483
Colgate-Palmolive CompanyFDA 483 - Colgate-Palmolive Company - May 30, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
The FDA inspected Colgate Palmolive Company's Corporate Headquarters in Piscataway, NJ, and issued a Form 483 with one observation. The firm failed to submit copies of product labels with serious adverse event reports for OTC Monograph non-prescription drugs. This indicates a deficiency in their adverse event reporting process.
Open in Dashboard
ID · 62186d39-57c7-438a-aae3-42bd3b0eda0c